A Study of the Pharmacokinetics and Safety of SM03 in Patients With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2013-12-16
Target enrollment:
Participant gender:
Summary
This was an open phase I trial to evaluate the pharmacokinetic, pharmacodynamic, safety and
clinical activity profiles of anti-CD22 monoclonal antibody SM03 in patients with active RA.